HLS Therapeutics (HLS) Stock Price, News & Analysis

Company Overview

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

Key Stats

• Today's Range: C$3.97 to C$4.03
• 50-Day Range: C$3.13 to C$4.00
• 52-Week Range: C$3.00 to C$5.48
• Volume: 4,901 shs
• Average Volume: 29,556 shs
• Market Capitalization: C$126.84 million
• P/E Ratio: N/A
• Dividend Yield: 5.01%
• Price Target: C$4.13
• Consensus Rating: Buy

HLS Stock Analysis - Frequently Asked Questions

How have HLS shares performed this year?

HLS Therapeutics' stock was trading at C$3.93 at the start of the year. Since then, HLS shares have increased by 1.5% and is now trading at C$3.99.
View the best growth stocks for 2025 here.

How were HLS Therapeutics' earnings last quarter?

HLS Therapeutics Inc. (TSE:HLS) issued its earnings results on Thursday, August, 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.22. The company earned $22.05 million during the quarter, compared to the consensus estimate of $21.17 million. HLS Therapeutics had a negative trailing twelve-month return on equity of 24.82% and a negative net margin of 40.90%.

How do I buy shares of HLS Therapeutics?

Shares of HLS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of HLS Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that HLS Therapeutics investors own include Toronto-Dominion Bank (TD), Meta Platforms (META), NVIDIA (NVDA), CohBar (CWBR), Alphabet (GOOG), Great-West Lifeco (GWO) and ObsEva (OBSV).

Company Calendar

• Last Earnings: 8/10/2023
• Today: 1/19/2025

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: TSE:HLS
• CUSIP: N/A
• CIK: N/A
• Web: www.hlstherapeutics.com
• Phone: 647-495-9000
• Fax: N/A
• Employees: 91
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: C$4.13
• High Stock Price Target: C$5.00
• Low Stock Price Target: C$3.25
• Potential Upside/Downside: +3.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): C($1.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-24,090,000.00
• Net Margins: -40.90%
• Pretax Margin: N/A
• Return on Equity: -24.82%
• Return on Assets: -2.89%

Debt

• Debt-to-Equity Ratio: 100.44
• Current Ratio: 2.02
• Quick Ratio: 1.01

Sales & Book Value

• Annual Sales: C$58.89 million
• Price / Sales: 2.15
• Cash Flow: C$0.26 per share
• Price / Cash Flow: 15.22
• Book Value: C$2.60 per share
• Price / Book: 1.53

Miscellaneous

• Outstanding Shares: 31,790,000
• Free Float: N/A
• Market Cap: C$126.84 million
• Optionable: Not Optionable
• Beta: 1.07